Last kr177.00 SEK
Change Today +2.00 / 1.14%
Volume 4.0K
BIOGB On Other Exchanges
Symbol
Exchange
OTC US
Berlin
Stockholm
As of 4:24 AM 04/16/14 All times are local (Market data is delayed by at least 15 minutes).

biogaia ab-b shs (BIOGB) Snapshot

Open
kr175.50
Previous Close
kr175.00
Day High
kr177.50
Day Low
kr175.50
52 Week High
09/11/13 - kr257.00
52 Week Low
04/11/14 - kr168.00
Market Cap
3.1B
Average Volume 10 Days
94.9K
EPS TTM
kr3.57
Shares Outstanding
16.5M
EX-Date
05/7/14
P/E TM
49.6x
Dividend
kr3.35
Dividend Yield
5.63%
Current Stock Chart for BIOGAIA AB-B SHS (BIOGB)

Related News

No related news articles were found.

biogaia ab-b shs (BIOGB) Related Businessweek News

No Related Businessweek News Found

biogaia ab-b shs (BIOGB) Details

BioGaia AB develops, markets, and sells probiotic products with documented health benefits worldwide. The company operates through Finished Consumer Products, Component Products, and Other Products segments. It offers products for the treatment of acute diarrhoea, constipation, helicobacter pylori infection, infant colic, regurgitation, and gingivitis, as well as for digestive and oral health. The company offers BioGaia ProTectis digestive health probiotic drops for children; BioGaia ProTectis D3 drops with vitamin D3 containing lactobacillus reuteri protectis for children; and BioGaia ProTectis ORS, a probiotic oral rehydration solution with zinc. It also provides BioGaia ProTectis chewable tablet, a dietary supplement containing lactobacillus reuteri protectis for children and adults; BioGaia ProDentis oral lozenges, a dietary supplement containing lactobacillus reuteri prodentis for children and adults; ProDentis oral health tablet; and BioGaia ProTectis straw that provides lactobacillus reuteri protectis to any beverage. In addition, the company offers component products, which are bacterial cultures of lactobacillus reuteri protectis that are used as ingredients in infant formula and cereal products, yoghurt, and other dairy products. Further, it offers animal health products. The company sells its products through pharmacies, drug stores, and retail outlets. BioGaia AB was founded in 1990 and is headquartered in Stockholm, Sweden.

85 Employees
Last Reported Date: 02/12/14
Founded in 1990

biogaia ab-b shs (BIOGB) Top Compensated Officers

Founder, Chief Executive Officer, President, ...
Total Annual Compensation: kr2.1M
Compensation as of Fiscal Year 2012.

biogaia ab-b shs (BIOGB) Key Developments

Biogaia AB and Nestle Signs a New Agreement

Biogaia AB and Nestle had signed a new agreement, supplementary to the one from February 2012, in order to strengthen their partnership. The new agreement will result in royalties of about SEK 92 million (USD 14.4 million/EUR 10.4 million) for the biotech company over a period of three years, starting in the second quarter of 2014. Under the terms of the new agreement, BioGaia will carry out specific clinical studies in the paediatric area, while developing new products in new areas for Nestle. The new agreement will have a positive impact on BioGaia's profit during this three-year period as the group has already planned on carrying out some of the trials it covers. The company will also immediately receive the remaining EUR 7.2 million milestone payments pending under the 2012 agreement.

BioGaia Proposes Ordinary and Extraordinary Dividend

The Board of Directors of BioGaia proposed that the company pay an ordinary dividend of SEK 3.35, and, in view of the company's good liquidity and strong balance sheet, an extraordinary dividend of SEK 3.65, amounting to a total dividend of SEK 7.00 per share. This is equal to a total distribution of SEK 120.9 million.

BioGaia AB Reports Consolidated Earnings Results for the Fourth Quarter and Parent and Consolidated Earnings Results for the Year Ended December 31, 2013

BioGaia AB reported consolidated earnings results for the fourth quarter and parent and consolidated earnings results for the year ended December 31, 2013. For the quarter, on consolidated basis, the company’s net sales amounted to SEK 90,221,000 against SEK 72,403,000 a year ago. Operating profit was SEK 23,773,000 against SEK 13,139,000 a year ago. Profit before tax was SEK 21,910,000 against SEK 13,552,000 of prior year period. Profit for the period was SEK 16,294,000 against SEK 15,807,000 a year ago. Profit attributable to owners of the parent company was SEK 16,300,000 against SEK 14,855,000 a year ago. Basic and diluted earnings per share were SEK 0.94 against SEK 0.86 a year ago. Cash flow used in operating activities was SEK 2,045,000 against cash used in operating activities was SEK 23,520,000 a year ago. For the year, on consolidated basis, the company’s net sales amounted to SEK 315,875,000 against SEK 289,248,000 a year ago. Operating profit was SEK 81,653,000 against SEK 428,070,000 a year ago. Profit before tax was SEK 83,760,000 against SEK 442,242,000 of prior year period. Profit for the period was SEK 64,188,000 against SEK 329,871,000 a year ago. Profit attributable to owners of the parent company was SEK 61,722,000 against SEK 326,970,000 a year ago. Diluted earnings per share were SEK 3.56 against SEK 18.93 a year ago. Cash flow from operating activities was SEK 78,441,000 against SEK 335,557,000 a year ago. Return on average equity was 16% against 96% a year ago. Profit before tax was lower than in the previous year, mainly due to a loss on forward exchange contracts. Investments in property, plant and equipment amounted to SEK 16.6 million against SEK 29.4 million a year ago. For the year, on parent basis, the company’s net sales amounted to SEK 304,624,000 against SEK 278,515,000 a year ago. Operating profit was SEK 84,155,000 against SEK 428,825,000 a year ago. Profit before tax was SEK 186,261,000 against SEK 325,547,000 of prior year period. Profit for the period was SEK 144,657,000 against SEK 239,277,000 a year ago. Cash flow from operating activities was SEK 73,764,000 against SEK 323,379,000 a year ago.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BIOGB:SS kr177.00 SEK +2.00

BIOGB Competitors

Market data is delayed at least 15 minutes.

Company Last Change
BLIS Technologies Ltd $0.01 NZD 0.00
Danone SA €52.56 EUR -0.71
Oragenics Inc $2.48 USD 0.00
Probi AB kr41.00 SEK 0.00
Yakult Honsha Co Ltd ¥5,160 JPY +100.00
View Industry Companies
 

Industry Analysis

BIOGB

Industry Average

Valuation BIOGB Industry Range
Price/Earnings 49.2x
Price/Sales 9.6x
Price/Book 9.5x
Price/Cash Flow 46.9x
TEV/Sales 8.4x
 | 

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BIOGAIA AB-B SHS, please visit www.biogaia.se. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.